タイトルまたは説明

Product introduce：Lurasidone belongs to Class 3.1 of chemical registration classification and is suitable for the treatment of schizophrenia. Lurasidone (SM*****6) is an antagonist of dopamine D2 and *-HT7, with IC*0 values of 1.*8 and 0.**5 nM, respectively. Lurasidone (SM*****6) is also a partial agonist of *-HT1A receptor with IC*0 value of 6.*5 nM.

Function：Lurasidone is used to treat mental illness. The second generation (atypical) antipsychotic drug Lurasidone has high affinity for dopamine D2 receptor, serotonin *- HT2A receptor and *-HT7 receptor. Many clinical trials show that it can improve psychotic symptoms, emotional symptoms and cognitive symptoms of schizophrenia patients, and has the safety advantages of little influence on glucose and lipid metabolism indexes and prolactin.

Origin：Lurasidone is an atypical antipsychotic drug developed by Dainippon Sumitomo Pharmaceutical Company of Japan. On October *8th, ***0, the US Food and Drug Administration (FDA) approved its marketing under the trade name Latuda for the treatment of schizophrenia.